Abstract
Anticentromere antibodies (ACA) are associated with systemic sclerosis (scleroderma) patients exhibiting the more benign or so called limited manifestation of the disease (ISSc). ACA reactivity is directed against multiple polypeptide targets, the smallest of which is designated CENP-A. CENP-A is not an abundant cellular constituent; therefore to maximize recovery, we developed a protocol with a minimum of steps to isolate CENP-A from a human cell line. The trace cellular amount of this protein clearly dictated the production of its recombinant counterpart to facilitate determination of the role of the CENP-A antigen in scleroderma pathogenesis. Here, we describe the eukaryotic expression of CENP-A cDNA using baculovirus- mediated infection of insect cells. The non-fusion recombinant protein spans the natural residues of the human CENP-A protein and rCENP-A followed the same chromotographic sequence for purification as did the natural source. The availability of the bona fide antigen provided a critical standard upon which to document authenticity of the recombinant polypeptide. The two forms of this antigen have been compared and shown to exhibit similar physical and antigenic properties.
| Original language | English |
|---|---|
| Pages (from-to) | 611-619 |
| Number of pages | 9 |
| Journal | Journal of Autoimmunity |
| Volume | 11 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 1998 |
| Externally published | Yes |
Keywords
- Anticentromere antibodies (ACA)
- Human CENP-A
- Recombinant CENP- A
- Scleroderma
- SSc